What is Tirzepatide?
Tirzepatide is a dual agonist targeting both the GIP and GLP-1 receptors. It is FDA-approved for type 2 diabetes and chronic weight management, and has shown strong effects on glycemic control and body weight in trials.
Also known as: GIP/GLP-1 dual agonist
How Tirzepatide is studied
Tirzepatide is a "dual agonist" that activates both the GIP and GLP-1 receptors. Engaging two incretin pathways appears to produce strong effects on appetite, blood sugar, and body weight, and it is FDA-approved for type 2 diabetes and chronic weight management.
Commonly researched for
Research status
Important considerations
Prescription medication with known side effects. Use only under medical supervision.
Tirzepatide — frequently asked questions
Type 2 diabetes and chronic weight management, supported by large clinical trials. It targets both GIP and GLP-1 receptors.
Trials have shown substantial glycemic and weight effects, but comparisons should be interpreted by a clinician for your situation. Both are prescription medications.
Yes — most commonly gastrointestinal, similar to other incretin drugs. It should be used under medical supervision.